JC PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
JC PHARMA
Largest movements
- Current investments -€731,840
down €731,840 (-60.6%), from €1.2m to €475,000
- Receivables within one year +€605,118
up €605,118 (+168.6%), from €358,933 to €964,051
of which Other amounts receivable: +€586,991
- Cash +€145,573
new in 2025: €145,573
mainly Current investments (+€731,840) and Net result for the year (+€216,126)
- Reserves +€216,126
up €216,126 (+21.8%), from €990,812 to €1.2m
- Trade debts -€123,266
down €123,266 (-22.3%), from €553,475 to €430,209
- Other debts -€57,958
down €57,958 (-65.9%), from €88,004 to €30,046
- Gross operating margin +€245,640
up €245,640 (+309.1%), from €79,474 to €325,114
- Taxes +€79,239
up €79,239 (+297.7%), from €26,620 to €105,858
- Financial income -€10,564
down €10,564 (-30.0%), from €35,247 to €24,683
- Financial charges -€3,512
down €3,512 (-15.9%), from €22,045 to €18,533
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,725,241 | €1,753,214 | +€27,973 | +1.6% |
| Fixed assets | 21/28 | €15,536 | €14,267 | -€1,269 | -8.2% |
| Tangible fixed assets | 22/27 | €15,536 | €14,267 | -€1,269 | -8.2% |
| Plant, machinery and equipment | 23 | €10,541 | €9,968 | -€573 | -5.4% |
| Furniture and vehicles | 24 | €4,996 | €4,299 | -€697 | -13.9% |
| Current assets | 29/58 | €1,709,705 | €1,738,947 | +€29,242 | +1.7% |
| Stocks and contracts in progress | 3 | €143,932 | €154,323 | +€10,391 | +7.2% |
| Stocks | 30/36 | €143,932 | €154,323 | +€10,391 | +7.2% |
| Amounts receivable within one year | 40/41 | €358,933 | €964,051 | +€605,118 | +168.6% |
| Trade receivables | 40 | €238,518 | €256,645 | +€18,127 | +7.6% |
| Other amounts receivable | 41 | €120,415 | €707,406 | +€586,991 | +487.5% |
| Current investments | 50/53 | €1,206,840 | €475,000 | -€731,840 | -60.6% |
| Cash at bank and in hand | 54/58 | - | €145,573 | +€145,573 | |
| Total equity and liabilities | 10/49 | €1,725,241 | €1,753,214 | +€27,973 | +1.6% |
| Equity | 10/15 | €997,012 | €1,213,138 | +€216,126 | +21.7% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Reserves | 13 | €990,812 | €1,206,938 | +€216,126 | +21.8% |
| Distributable reserves | 133 | €990,812 | €1,206,938 | +€216,126 | +21.8% |
| Amounts payable | 17/49 | €728,229 | €540,076 | -€188,153 | -25.8% |
| Amounts payable within one year | 42/48 | €728,229 | €540,076 | -€188,153 | -25.8% |
| Trade debts | 44 | €553,475 | €430,209 | -€123,266 | -22.3% |
| Suppliers | 440/4 | €553,475 | €430,209 | -€123,266 | -22.3% |
| Taxes, remuneration and social security | 45 | €86,750 | €79,821 | -€6,929 | -8.0% |
| Taxes | 450/3 | €86,750 | €79,821 | -€6,929 | -8.0% |
| Other amounts payable | 47/48 | €88,004 | €30,046 | -€57,958 | -65.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €8,168 | €9,131 | +€963 | +11.8% |
| Other operating charges | 640/8 | €1,116 | €149 | -€968 | -86.7% |
| Gross operating margin | 9900 | €79,474 | €325,114 | +€245,640 | +309.1% |
| Operating profit (loss) | 9901 | €70,190 | €315,834 | +€245,644 | +350.0% |
| Financial income | 75/76B | €35,247 | €24,683 | -€10,564 | -30.0% |
| Recurring financial income | 75 | €35,247 | €24,683 | -€10,564 | -30.0% |
| Financial charges | 65/66B | €22,045 | €18,533 | -€3,512 | -15.9% |
| Recurring financial charges | 65 | €22,045 | €18,533 | -€3,512 | -15.9% |
| Profit (loss) for the period before taxes | 9903 | €83,392 | €321,985 | +€238,592 | +286.1% |
| Income taxes | 67/77 | €26,620 | €105,858 | +€79,239 | +297.7% |
| Profit (loss) for the period | 9904 | €56,772 | €216,126 | +€159,354 | +280.7% |
| Profit (loss) for the period to be appropriated | 9905 | €56,772 | €216,126 | +€159,354 | +280.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.